Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects With Dry Eye Disease

NCT03916042 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT03916042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03916042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects With Dry Eye Disease
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2019
Completion date
November 22, 2019
Enrollment
206 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye